Pfizer, Microsoft sue over illegal Viagra

	Tweet

Pfizer Inc. and Microsoft Corp. said on Thursday they filed parallel lawsuits against Web site operators and spam advertisers that they say sell illegal cheap versions of Pfizer’s Erectile dysfunction drug Viagra (sildenafil).

The companies said the lawsuits follow a seven-month investigation to discover the identity of two Web site operators together with those advertising them via spam e-mails.

Pfizer has filed suit against CanadianPharmacy and E-Pharmacy Direct, while Microsoft has filed civil actions against the spam advertisers for the Web sites. Microsoft has also filed three suits against spam advertisers who advertise on other online pharmacies.

--------------------------------------------------------
VIAGRA © is the top selling prescription medication for Erectile Dysfunction (also known as impotence). Over 16 million men have used Viagra for the treatment of erectile dysfunction.

Order Viagra online!
--------------------------------------------------------

RELATED STORIES:
Hib vaccines act differently in old and young   New Guidelines for Prescribing Opioid Pain Drugs Published   FDA approves automated hepatitis C virus assay on ADVIA Centaur Immunoassay system   India drug firm pulls antiretrovirals from WHO list   E-prescribing Systems Can Boost Drug Cost Savings   GlaxoSmithKline announces start of clinical trials to test two pandemic vaccines against the H5N1   Merck may settle some Vioxx cases, NJ trial looms   Pfizer Lipitor study has mixed results   Progress made toward gonorrhea vaccine   FDA Approves Novartis Hypertension Drug   Eli Lilly played down risks of top drug   Vardenafil improves peripheral blood flow in Raynaud disease

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]